SCHEMBL7239674

SCHEMBL7239674

O=C(O)c1ccccc1C(=O)Nc1nc(-c2ccc3c(c2)CCCC3)cs1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.71
MEN1 O00255 8/20 0.57
KMT2A Q03164 8/20 0.57
MAPT P10636 6/20 0.57
NPC1 O15118 4/20 0.54
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
RRM1 P23921 1/20 0.52
RRM2B Q7LG56 1/20 0.52
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
POLB P06746 1/20 0.52
HTT P42858 1/20 0.52
HPGD P15428 2/20 0.51
STAT1 P42224 1/20 0.51
GFER P55789 1/20 0.51
MRE11 P49959 1/20 0.50
ROCK1 Q13464 1/20 0.49
TP53 P04637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7239062 0.83 RAB9A (1.00) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7236472 0.82 RAB9A (0.77) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7236195 0.81 RAB9A (0.75) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7232167 0.81 RAB9A (0.75) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7231250 0.80 MAPT (0.76) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7240555 0.80 RAB9A (0.71) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL9333370 0.80 KMT2A (0.59) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7235913 0.79 RAB9A (0.83) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL9336145 0.79 MAPT (0.51) RAB9AMEN1KMT2AMAPTNPC1
SCHEMBL7235868 0.78 RAB9A (0.71) RAB9AMEN1KMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-20 US disclosed
WO-2003006443-A2 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055263-A1 Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production TERT, POT1, REV1 RAB9A 3964/4885MEN1 386/4885KMT2A 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.